RDDT Deadline: Rosen Law Firm Urges Reddit, Inc. (NYSE: RDDT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights 
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements 
WL Delicious Announced 2025 Interim Results First-of-its-Kind App, TheStreet Powered by Tornado, Launches One-Stop Investing Experience
Sleek Trading Platform Brings Curated Stock Market News, Data, and Expert Analysis – Plus a…
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic…
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic…
22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution
Enhances Reach for Regional, Specialty and Tribal Retail Channels BUFFALO, N.Y., July 12, 2023 (GLOBE…
22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution
Enhances Reach for Regional, Specialty and Tribal Retail Channels BUFFALO, N.Y., July 12, 2023 (GLOBE…
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
Received record quarterly sepsis test panel orders and strengthened balance sheet LEXINGTON, Mass., July 12,…
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
Received record quarterly sepsis test panel orders and strengthened balance sheet LEXINGTON, Mass., July 12,…
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments…
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments…
Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Akoya to Report Second Quarter 2023 Financial Results on August 7th, 2023
MARLBOROUGH, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Apnimed, Inc., a clinical-stage pharmaceutical company focused…
Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) — Apnimed, Inc., a clinical-stage pharmaceutical company focused…
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
SHANGHAI, China and PRINCETON, N.J., July 12, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023…
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023…
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing…
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing…
Ocular Therapeutixâ„¢ Announces Appointment of New Board Member
Dr. Adrienne Graves to join Board of Directors BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE)…